Our team at Notable Labs is looking forward to attending the twelfth annual meeting of the Society of Hematologic Oncology (SOHO 2024), September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas. We look forward to learning about the latest breakthroughs in the research and treatment of patients with hematologic malignancies and collaborating in real time with our colleagues. Contact us at https://lnkd.in/eAgN3cFt to set up an appointment. #SOHO2024 #hemonc #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS
Notable’s Post
More Relevant Posts
-
The countdown is on! From December 7 to 10, 2024 #ASH24 will be all about groundbreaking advances in hematology. Our experts on #high5oncology will present the latest findings, discuss current topics, and offer an exciting glimpse into the future of medicine. Stay tuned and follow us to catch all the highlights and gain exclusive behind the scenes insights into the event! #Hematology #BloodHealth #MedicineOfTheFuture #Oncology #BloodCancerResearch #CancerMedicine #Research #BloodDisorders #Science #CancerResearch #Leukemia
-
-
Keeping the key insights from European Hematology Association (EHA) 2024 coming! 💫 LARVOL CLIN has been diving into discussions from leading oncologists on X, focusing on the top trials. Discover more in our detailed analysis here: https://bit.ly/3VBTjHk #EHA2024 #LARVOL #Hematology #ClinicalTrials #Oncology
-
-
Next week at the American Society of Hematology Annual Meeting, we will be presenting first-time data from our Phase 1 study of ISB 2001, our first-in-class trispecific antibody, in relapsed or refractory multiple myeloma (RRMM). We are excited to share updated analysis with additional patient data beyond what’s featured in the abstract, available here: https://bit.ly/41fzybR. Thanks to Professor Hang Quach, M.D., for presenting this important data. #ASH24 #MultipleMyeloma #Hematology #InnovationInMedicine #Oncology #ClinicalTrials #CancerResearch
-
-
As European Hematology Association (EHA) 2024 approaches, LARVOL CLIN has curated key insights looking back at the top trials at EHA 2023, as discussed by 2500+ leading oncologists on X. To explore more insights from last year’s conference: https://bit.ly/3RpSIGh #EHA2023 #EHA2024 #LARVOL #Hematology #BloodCancer #BloodCancerResearch #Oncology #CancerResearch
-
-
Endpoints in malignant hematology studies differ significantly from those used for solid tumors. In this white paper, Christopher Morley and Sari Heitner Enschede, MD consider the most effective investigational agents for blood-based cancers. Download now. https://bit.ly/3U3HKrp #oncology #hematology #biotech #ClinicalTrials #diversity
-
-
🎥 Live from ESMO 2024! 🩺✨ At this year's European Society for Medical Oncology (ESMO) Annual Meeting, key studies (813MO, 814MO, 815MO, 816MO) are making waves in the field of hematological malignancies. 🧬🔬 In this video, we bring you insights from Professor Annarita Conconi from the University of Eastern Piedmont, Italy, who shares her thoughts on the preliminary but promising findings of these groundbreaking studies. Stay tuned for an expert perspective on how these research advancements could reshape the landscape of hematology. #ESMO2024 #Hematology #OncologyFrontier #MedicalResearch #CancerResearch #Oncology
-
Oncologist, MD; PhD student in Inflammation, Immunity and Cancer at University of Verona
🎉 Excited to share the findings from the multicenter real-world ARON-3 study, now published in European Urology Oncology! 📌 This study brings together global data on patients with prostate cancer, focusing on those with metastatic hormone-sensitive prostate cancer (mHSPC) treated with apalutamide. The analysis highlights that apalutamide remains a safe and effective treatment option in real-world practice, complementing the outcomes seen in clinical trials. Grateful to the ARON team for the collaboration! 📖 Read the full article here: https://lnkd.in/d8JJPUPW
-
-
Endpoints in malignant hematology studies differ significantly from those used for solid tumors. In this white paper, Christopher Morley and Sari Heitner Enschede, MD consider the most effective investigational agents for blood-based cancers. Download now. https://bit.ly/3Ar8o6r #oncology #hematology #biotech #ClinicalTrials #diversity
-
-
⚠ More and better treatments are needed to tackle #pancreaticcancer. But how do we get there? During a multistakeholder meeting, organised with Pancreatic Cancer Europe, key issues and opportunities were flagged. ✅ Find out more in the recap interview here below. #anticancerfund
This is the communication office of Pancreatic Cancer Europe (PCE). Connect with us to keep updated on events and conferences, as well as to network with experts, organisations and patients
On June 25, 2024, we had the honour of hosting the “Getting Our Act Together - The Multistakeholder Meeting on Access to Therapy for Pancreatic Cancer” in Santiago de Compostela, Spain. Together with the Anticancer Fund and supported by the European Pancreatic Club, the event brought together experts from oncology, surgery, gastroenterology, pharmacology, patient advocacy, and policy-making. Today, we are excited to share a recap interview with Aiste Gulla from Vilnius University’s Clinic of Gastroenterology, Nephrourology, and Surgery in Lithuania. In the interview, Aistė shares her insights from the event, emphasising the importance of collaborative efforts in improving access to therapy for pancreatic cancer patients. Watch full interview here: https://lnkd.in/gaez56bd
-
✅FDA has approved Abecma® 4⃣ the tx of adult patients with relapsed or refractory multiple myeloma after4⃣➕prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, & an anti-CD38 monoclonal antibody LEARN MORE➡️https://lnkd.in/e8QJHJA9 #multiplemyeloma #myeloma #drugapprovals #bloodcancer #oncology #hematology
Markus Lacher Glenn Michelson Joseph Wagner Chris Leonardi